ArticleDrug and alcohol dependence2026
Safer supply deprescribing during a toxic drug poisoning crisis in Vancouver, Canada.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSince 2016, more than 53,000 Canadians have died from exposure to the toxic unregulated drug supply. In 2020, the British Columbia government implemented a program in which pharmaceutical alternatives to toxic unregulated drugs can be prescribed, known as "prescribed safer supply." Since 2023, the number of prescriptions and prescribers has declined, and people who use drugs (PWUD) in Vancouver have reported community-wide deprescription. We sought to examine the prevalence and predictors of deprescribing in Vancouver, BC.
methodsUsing data from two Vancouver-based prospective cohorts of PWUD, we included participants who self-reported accessing prescribed safer supply. Generalized estimating equations were used to identify factors associated with deprescribing.
resultsBetween December 2023 and November 2024, 353 eligible participants were included; 62 (17.6%) were deprescribed. In multivariable analyses, gender self-identification as a woman (adjusted odds ratio [AOR] = 1.92; 95% confidence interval [CI]: [1.06, 3.49]), nonfatal overdose (AOR = 3.35; 95% CI: [1.81, 6.17]), and challenges accessing addiction treatment (AOR = 4.51; 95% CI: [2.48, 8.21]) were positively associated with increased odds of deprescription. Among those deprescribed, 88.7% were deprescribed from tablet hydromorphone. Deprescribed participants reported increased use of unregulated drugs and negative health and social impacts. Negative urine drug screen results (38.7%), missed medication pickup or delivery (24.2%), and diversion (22.6%) were reported as reasons for deprescription.
conclusionIt remains unclear whether deprescribed patients are transitioned to other safer supply medications or drug treatments. More work is needed to assess the scope of safer supply deprescribing and illuminate its social-structural drivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.